Special Guest · 8:00–8:15 AM PT
?
Special guest
Pre-session & community (captured 06/15/2026):
• GUEST DEMO — ExpertScale / Apex Replicant (expertscale.ai), presented informally by a member (Ellen/Alan). An AI-powered conversational clinical-interview tool — a "protégé" modeled on a specific clinician (not a chatbot/agent). No-hallucination guarantee, HIPAA-compliant, PII-stripped for demographic research; captures far richer data than pain-scale forms. Use cases: clinical intake, knowledge preservation for retiring SMEs, enterprise training reduction (one firm 5mo→1mo; Cisco digitized 96 SMEs as 24/7 "digital doubles"). Clinical trial underway; positive early feedback, esp. older patients. WSJ noted Nvidia entering a similar space. ACTION: consider organizing an "Ellen AI Monday" working group on ExpertScale/Apex Replicant. [Candidate to add to MM Member Directory/Groups if not already — flag.]
• Announcements: Nuvox seeking capital (promising studies, underfunded) — reach out privately. Gastric-motility specialist referral needed in Atlanta (check Emory GI / Hopkins; David to share David Greenwald, past GI Society president).
• POST-MEETING INVESTMENT-STRATEGY DISCUSSION: all three of today's deals seen by multiple members as overvalued for their stage. Debate on whether MM should reconsider pharma / repurposed-drug deals — consensus = CASE-BY-CASE judgment on deal economics, NOT a blanket exclusion. Fund-vs-individual dynamic noted (moonshots like Ardia suit a portfolio fund, hard as individual angel checks; angel funds often can't do follow-ons). Reaffirmed filter: valuation/structure must fit stage, capital-to-exit, and realistic return range — not just whether the tech works.
• Separate same-day call (not this session): "Medical Mondays & BioCom Introductory Collaboration Call."
Pitches · 8:15–9:30 AM PT
Prana Surgical
Joanna Nathan, CEO · joanna@pranasurgical.com
↩ Previously pitched at Medical Mondays · March 11, 2024
Prana Surgical is developing a minimally invasive, image-guided surgical platform for intervening in early-stage lung cancer
Round
$10M Priced Round @ $25M pre-money valuation
Closed
$1.75M
FDA milestone
FDA 510(k) Clearance, FIH complete (n=10)
FDA timeline
Complete
Other groups in round
Texas Medical Center Venture Fund, New World Angels
DD package
Yes
Traction: FDA Clearance
After the session
Public-facing recap for the MM website. Counts only — no investor names, emails, or group names.
Investor sentiment (33 responses)
Investor engagement
1
6 investors invited the company to apply to their group; 3 more asked to connect 1
- Lead investor on board; an early lead angel group signaled it will invest in the second closing
- DD materials requested by multiple members
Q&A themes
- Investors asked about commercial adoption speed and ramp, IP defensibility, patient selection, and reimbursement/exit pathway
- 510(k) cleared; 10-patient First-in-Human complete (9/10 nodules reached; 6/9 positive findings; no significant bleeding or pneumothorax)
Summary
Strong reception. Primary discussion centered on adoption velocity and valuation relative to stage; the underlying clinical data and lead-investor support were viewed as differentiators.
Materna Medical
Tracy MacNeal, CEO · tracy@maternamed.com
Materna Medical is a novel OBGYN platform company that defines a $25B market in the most common pelvic conditions women face. Our first product, Milli, is an expanding vaginal dilator used to treat patients suffering from painful sex due to chronic vaginal tightness (vaginismus). Materna’s second product, Ellora, is a clinical-stage device aiming to help women have a faster delivery with less chance of injury to their pelvic floor muscles.
Round
$6M Priced Round @ $37.5M
Closed
$4.5M
FDA milestone
FDA clearance on first product, De Novo submission on second product
FDA timeline
Submitting 3Q2026, anticipate approval 1Q2027
Other groups in round
Wavemaker 360 Health (LA), Golden Seeds, Band of Angels, Houston Angel Network, Frontier Angels
DD package
Yes
Traction: Revenue on first product, reimbursement code with letters of support from societies on second product
What they're looking for: Marketing leaders, payer introductions for pre-commercial benchmarks
After the session
Public-facing recap for the MM website. Counts only — no investor names, emails, or group names.
Investor sentiment (30 responses)
Investor engagement
1
2 investors requested a 1
- 1 investor will reconsider at the next round
- Long-standing investors spoke in support during the session
Q&A themes
- Discussion centered on valuation and capital structure relative to stage rather than the technology
- Reimbursement realization, liquidation preference / waterfall, and realistic return range were the main topics
- Clinical data (statistically significant 80% reduction in pelvic floor injury; imminent pivotal readout) was well received
Summary
A late-stage, clinically de-risked women's-health device. The room valued the data but debated deal economics — valuation versus stage, capital efficiency, and the expected return profile.
ARDIA Therapeutics
Bryan Jones, CEO · bjones@ardiatherapeutics.com
Ardia (DIA-615) is a clinical-stage dermatology therapeutic — a topical reformulation of sodium phenylbutyrate (a chemical chaperone that corrects misfolded proteins and reduces ER stress) for orphan skin diseases, lead indications cutaneous lupus and epidermolysis bullosa. 505(b)(2) regulatory pathway leveraging the oral parent drug's safety data. Wholly owned spin-out of Aardvark (NASDAQ); all IP assigned to Ardia.
Round
$2M Convertible Note @ $15M pre-money
Closed
$0 external (~$2M invested to date by parent Aardvark)
FDA milestone
505(b)(2); Phase 1 adaptive trial planned (10–15 patients each in cutaneous lupus and EB); intra-patient control design
FDA timeline
18–24 months to complete Phase 1
Other groups in round
Currently funded by Nasdaq company (AARD)
DD package
n/a
Traction: In vitro cell-differentiation data; case observations (psoriatic arthritis, diabetic wound, EB); proprietary topical formulation (patents pending), CMC complete, manufacturer ready
After the session
Public-facing recap for the MM website. Counts only — no investor names, emails, or group names.
Investor sentiment (22 responses)
Investor engagement
- 2 investors invited the company to apply to their group
- The orphan-drug path was noted as carrying potential priority-review-voucher value
Q&A themes
- Discussion centered on valuation/stage fit, parent-company governance, orphan market size, and the crowded competitive landscape for the larger indications
- Only preclinical/anecdotal data to date
Summary
An early, preclinical repurposed-drug program in orphan dermatology. The science drew interest, but the room's gating concerns were valuation relative to stage and governance/control rather than the underlying mechanism.